Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581363 | 1.00 | GRM5 (0.51) | GRM5CHRNB2CHRNA4ADORA1CYP1A2 | |
| SCHEMBL921576 | 0.87 | L3MBTL1 (0.54) | ADORA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL318649 | 0.83 | GRM5 (0.48) | GRM5CHRNB2CHRNA4L3MBTL1NTRK1 | |
| SCHEMBL10691207 | 0.81 | ADORA1 (0.46) | ADORA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13489802 | 0.81 | ADORA1 (0.48) | ADORA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19718960 | 0.81 | ADORA1 (0.48) | ADORA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL126159 | 0.81 | RAB9A (0.68) | GRM5RAB9APOLBMEN1GBA1 | |
| SCHEMBL30485981 | 0.81 | RAB9A (0.68) | GRM5RAB9APOLBMEN1GBA1 | |
| SCHEMBL1432533 | 0.80 | KDM4E (0.61) | GRM5CHRNB2CHRNA4ADORA1NTRK1 | |
| SCHEMBL336194 | 0.80 | SORT1 (0.50) | GRM5ADORA1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981854-B | Synthesis method of 2-amino-6- (1-alkyl piperidine-4-carbonyl) pyridine compound | 南京三元阳普医药科技有限公司 | 2023-03-28 | — | — | CN | claimed |
| US-20110105566-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-05 | — | — | US | claimed |
| US-6469172-B2 | 2-AMINO-6-((4-AMINOPIPERIDIN-1-YL)METHYL)PYRIDINE; CHEMICAL INTERMEDIATE FOR MUSCARINIC M3 RECEPTOR ANTAGONISTS; ACYLATION OF 2-AMINO-6-BROMOPYRIDINE WITH TRIMETHYLACETIC ACID | MERCK & CO., INC. | 2002-10-22 | — | — | US | claimed |
| US-20010051727-A1 | Process for the preparation of chemical compounds | MERCK& CO., INC. | 2001-12-13 | — | — | US | claimed |
| EP-3994131-B1 | 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN | MOEHS IBERICA SL (ES) | 2023-05-24 | — | — | EP | disclosed |
| EP-3994131-B1 | 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN | MOEHS IBERICA SL (ES) | 2023-05-24 | — | — | EP | disclosed |
| CN-110981854-B | Synthesis method of 2-amino-6- (1-alkyl piperidine-4-carbonyl) pyridine compound | 南京三元阳普医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220306601-A1 | 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN | MOEHS IBERICA, S.L. (ES) | 2022-09-29 | — | — | US | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| WO-2021001350-A1 | 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN | MOEHS IBERICA, S.L. (ES) | 2021-01-07 | — | — | WO | disclosed |
| EP-3749305-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Université de Strasbourg (FR) | 2020-12-16 | — | — | EP | disclosed |
| CN-111683660-A | Compounds and compositions for the treatment of pain | 斯特拉斯堡大学 | 2020-09-18 | — | — | CN | disclosed |
| CN-1323211-A | New pharmaceutical use of NOS inhibitors | PFIZER PROD INC (US) | 2001-11-21 | — | — | CN | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| CN-1268133-A | 2-Aminopyridines containing fused ring substituents as NOS inhibitors | PFIZER PROD INC (US) | 2000-09-27 | — | — | CN | disclosed |
| CN-1268122-A | Branched alkoxy- substituted 2-aminopyridines as NOS inhibitors | PFIZER PROD INC (US) | 2000-09-27 | — | — | CN | disclosed |
| EP-1007512-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999011620-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | GRM5 266/4885CHRNB2 748/4885CHRNA4 540/4885 |
| US-20220306601-A1 | 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN | PMP22, PLP2, PTMA | GRM5 919/4885CHRNB2 938/4885CHRNA4 921/4885 |
| US-20110105566-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | HAAO, CYP51A1, HPD | GRM5 603/4885CHRNB2 4806/4885CHRNA4 4677/4885 |
| US-20010051727-A1 | Process for the preparation of chemical compounds | CHRM3, CHRM5, CHRM2 | GRM5 187/4885CHRNB2 23/4885CHRNA4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.